open access
Biokinetics of 131I after endogenous and exogenous stimulation of TSH in patients with DTC
open access
Abstract
MATERIAL AND METHODS: Two groups of 50 patients were enrolled in the study. All patients were treated with 3.7 GBq of 131I; the first group after thyroid hormone withdrawal (THW), the second group after rhTSH administration (rhTSH). On the basis of post-treatment images, the uptake ratios over selected ROIs (thyroid remnants, mediastinum, liver, stomach, abdomen, and whole-body) were compared between groups.
RESULTS: In the case of uptake over the whole-body and the liver, statistically significant higher values were received for the THW group. For the remaining regions, the differences between groups were statistically insignificant, but uptake ratios in the rhTSH group were generally numerically lower compared to the THW group.
CONCLUSIONS: The revealed difference in radioiodine biokinetics after thyroid hormone withdrawal or administration of recombinant human TSH may influence many important aspects of patients with DTC treatment, such as the choice of proper therapeutic scheme, the cost of therapy, and the dose assessment.
Nuclear Med Rev 2010; 13, 2: 55–58
Abstract
MATERIAL AND METHODS: Two groups of 50 patients were enrolled in the study. All patients were treated with 3.7 GBq of 131I; the first group after thyroid hormone withdrawal (THW), the second group after rhTSH administration (rhTSH). On the basis of post-treatment images, the uptake ratios over selected ROIs (thyroid remnants, mediastinum, liver, stomach, abdomen, and whole-body) were compared between groups.
RESULTS: In the case of uptake over the whole-body and the liver, statistically significant higher values were received for the THW group. For the remaining regions, the differences between groups were statistically insignificant, but uptake ratios in the rhTSH group were generally numerically lower compared to the THW group.
CONCLUSIONS: The revealed difference in radioiodine biokinetics after thyroid hormone withdrawal or administration of recombinant human TSH may influence many important aspects of patients with DTC treatment, such as the choice of proper therapeutic scheme, the cost of therapy, and the dose assessment.
Nuclear Med Rev 2010; 13, 2: 55–58
Keywords
endogenous stimulation; exogenous stimulation; thyroid hormone withdrawal; recombinant human TSH; radioiodine treatment; DTC
About this articleTitle
Biokinetics of 131I after endogenous and exogenous stimulation of TSH in patients with DTC
Journal
Issue
Article type
Research paper
Pages
55-58
Published online
2011-05-20
Page views
992
Article views/downloads
1425
Bibliographic record
Nucl. Med. Rev 2010;13(2):55-58.
Keywords
endogenous stimulation
exogenous stimulation
thyroid hormone withdrawal
recombinant human TSH
radioiodine treatment
DTC
Authors
Monika Buziak-Bereza
Monika Tomaszuk
Dorota Pach
Anna Sowa-Staszczak
Agata Bałdys-Waligórska
Bogusław Głowa
Maciej Kołodziej
Alicja B. Hubalewska-Dydejczyk
